Abstract| Volume 20, ISSUE 5, SUPPLEMENT , S77-S78, May 2018

Selling stem cells with tokens of legitimacy: An analysis of websites in Japan and Australia

      The emergence of a global industry selling products and services marketed as stem cells directly-to-the-consumer (DTC) raises serious ethical concerns over patient safety and exploitation, conflicts of interest, clinical beneficence, distributive justice, and trust in science and medicine. Of particular concern, is the wide range of medical conditions that this industry targets without compelling evidence of safety and efficacy while presenting itself as being consistent with ethical and professional norms of scientific research and medical practice. By displaying symbols or ‘tokens of legitimacy’ in their marketing, businesses can ostensibly confer credibility and authenticity to operations that are inherently commercial and profit-orientated.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect